RevOpsis Therapeutics, an innovator in multispecific ophthalmic therapies, and Kemwell Biopharma, a top biologics CDMO, have announced a strategic partnership. This collaboration aims to accelerate the development of RevOpsis’ lead candidate, RO-104, a pioneering tri-specific biologic for treating (nAMD).
ophthalmic therapies

Accelerating Development of RO-104

Kemwell Biopharma will manufacture RO-104, a novel biologic targeting three key angiogenic pathways (VEGF-A, VEGF-C, Ang-2) linked to nAMD, a leading cause of blindness. RO-104’s ability to bind these targets positions it as a first-in-class monotherapy biologic, set to transform retinal disease treatment.


Leveraging Expertise for Expedited Development

Kemwell, operating India’s first commercial cGMP facility, brings extensive protein manufacturing expertise to the partnership. Combined with RevOpsis’ innovative Rev-Mod platform, this collaboration aims to expedite the development of multispecific biologics.

“Partnering with Kemwell is a pivotal step in accelerating the development of our lead candidate, RO-104, and advancing our pipeline of innovative multispecific biologics,” said Ram Bhandari, MD, Co-founder and Interim CEO of RevOpsis. “Kemwell’s track record in high-quality biologics manufacturing, combined with our proprietary Rev-Mod platform, ensures we can deliver transformative therapies efficiently.”

Anurag Bagaria, CEO of Kemwell Biopharma, added, “We are excited to collaborate with RevOpsis to manufacture and commercialize RO-104. This partnership underscores our commitment to delivering high-quality biologics for patients in need.”


Streamlined Therapeutic Discovery to IND Submission

This alliance provides RevOpsis with a critical solution to transition from pre-clinical activities to first-in-human clinical trials, expediting RO-104 and the broader platform development. Integrating RevOpsis’ multispecific biologics platform with Kemwell’s manufacturing expertise aims to streamline therapeutic discovery to IND submission timelines.


About RO-104

RO-104, leveraging the Rev-Mod platform, is RevOpsis’ lead candidate. It addresses three key angiogenic pathways (VEGF-A, VEGF-C, Ang-2) in retinal vascular disease progression, including nAMD, representing a significant advancement in treatment supported by preclinical evidence.


About Rev-Mod Platform

The Rev-Mod Platform employs a ‘plug-and-play’ approach to expedite the discovery and development of multispecific biologics for prevalent chronic diseases. It features a library of 30 billion fully human antibody components, enabling rapid identification and assembly of multispecific candidates.


About RevOpsis Therapeutics

Founded in 2018, RevOpsis Therapeutics is a biopharmaceutical company focused on ophthalmic therapies. Leveraging its proprietary Rev-Mod Platform, RevOpsis aims to develop groundbreaking treatments for chronic diseases.


About Kemwell Biopharma

Kemwell Biopharma is a leading CDMO providing development and manufacturing services for therapeutic proteins. Located in Bangalore, India, Kemwell offers end-to-end services for biopharmaceutical development and manufacturing.

Check out our AAV CDMO service to expedite your gene therapy research
About PackGene

PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.

Related News

Future Of Gamma Delta T Cell Therapies

Gamma delta T cell-based immunotherapies have emerged as a promising frontier in cancer treatment and beyond, building on the success of chimeric antigen receptor T-cell (CAR T cell) therapy and expanding on the potential of the immune system as a therapeutic...

read more

Related Services

Plasmids GMP Services

Multiple scales & grade of solutions of various kind of plasmids suitable for multiple treatments in a fast and cost effective way.

AAV GMP Services

Ranging from small-scale AAV production, to large-scale AAV cGMP manufacturing for animal studies.
aav icon

Technology Platforms

PackGene’s proprietary π-Alpha™ 293 AAV High-yield Platform increases AAV production by 3 to 8 times that of traditional platforms.